Data base for:

  • Conferences
  • Research funding opportunities
  • Competitions / Awards

Register for free and add any data by yourself!

See How to

Filter conferences

 
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
      
 
      
      
 
      
 
      
      
      
      
      
      
      
      
      
      
4th Liquid Biopsy for Precision Oncology East Coast

4th Liquid Biopsy for Precision Oncology East Coast

Categories

Date of beginning

Thursday, 26 June 2025

Duration

2 days

City

Boston

Country

United States

Contact

Isabel Weir

E-Mail

This email address is being protected from spambots. You need JavaScript enabled to view it.

Memo

The 4th Liquid Biopsy for Precision Oncology East Coast Summit returns to Boston with a refreshed agenda, sharpened focus, and a renewed mission: to accelerate access to more sensitive, less invasive testing by addressing the most pressing challenges across the entire patient care continuum.Bringing together leaders in Biomarker Development, Translational Research, Diagnostics, Clinical Development, Pathology, and beyond, this is the go-to East Coast forum for diving deep into the barriers slowing the adoption of liquid biopsy technologies.Take home actionable insights to ensure you're maximizing the value of liquid biopsies in your therapeutic development strategies. Shape the future of precision oncology, and be part of the conversations that will drive meaningful change for patients worldwide. URLs:Tickets: https://go.evvnt.com/2973730-2?pid=5569  Brochure: https://go.evvnt.com/2973730-3?pid=5569   Date and Time: Thu, 26 Jun 2025 07:50 - Fri, 27 Jun 2025 16:35 Venue details: The Colonnade Hotel, 120 Huntington Avenue, Boston, Massachusetts, 02116, United States Prices:Drug Developers and Researchers - *Free: USD 0.50,Solution Providers - On The Door: USD 3799.00 Speakers: Brian Dougherty, Director - Global Genomics and Translational Medicine Oncology, AstraZeneca, Duane Hassane, Head of Translational Omics, Hematology R AND D, AstraZeneca, Emily Chan, Executive Director – Oncology Global Development, Amgen, Joshua Levin, Director, Precision Medicine and Digital Health, GlaxoSmithKline, Minakshi Guha, Associate Director, LBx Strategy, Precision and Translational Medicine, Takeda Pharmaceutical, Radha Ramesh, Associate Director - Clinical Biomarker Lead - Oncology, Takeda Pharmaceutical, Raluca Predoiu, Director - Companion Diagnostic Strategy Lead, Abbvie, Supriya Shah, Director - Oncology Precision Medicine, Johnson and Johnson, David Wurtman, Chief Business Officer, Geneos Therapeutics, Inc., Ella Aguado, Associate Director - Translational Medicine, Repare Therapeutics, Haifa Ghandour, Associate Director - Diagnostic Lead, Alexion Pharma UK, John Boyce, President and CEO, BrickBio, Qing Li, Director, Pathology, Clinical Development, Oncology, Moderna, Carolina Reduzzi, Associate Professor and Director of Liquid Biopsies, Weill Cornell Medicine,, David Westenberg, Managing Director, Piper Sandler Companies, Jean Lopategui, Professor of Pathology, Cedars-Sinai Medical Center, Lauren Houghtalin, Director, Disease State, Technical Sales, BioIVT, Lauren Leiman, Executive Director, BloodPAC, Marina Milan, Project Manager, FNIH